Critical assessment of pharmaceutical processess - A rationale for changing the synthetic route

被引：175

作者：

Butters, Mike

Catterick, David

Craig, Andrew

Curzons, Alan

Dale, David

Gillmore, Adam

Green, Stuart P.

Marziano, Ivan

Sherlock, Jon-Paul

White, Wesley

机构：

[1] AstraZeneca, Proc R&D, Bristol BS10 7ZE, Avon, England

[2] GlaxoSmithKline, Synth Chem, Tonbridge TN11 9AN, Kent, England

[3] Pfizer, Chem R&D, PGR&D, Sandwich CT13 9NJ, Kent, England

来源：

CHEMICAL REVIEWS | 2006年 / 106卷 / 07期

关键词：

D O I：

10.1021/cr050982w

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

An overview is given of the most common types of issues in a pharmaceutical process. The review provides a uniform set of criteria (SELECT- safety, environmental, legal, economics, control, and throughput), which represent the different drivers for changing a synthetic route. Each criterion is illustrated by reference to examples that have been selected to highlight important features of each issue and to illustrate the positive benefits associated with a new route.

引用

页码：3002 / 3027

页数：26